Seres Therapeutics Inc (NAS:MCRB)
$ 0.915 0.038 (4.33%) Market Cap: 156.22 Mil Enterprise Value: 176.53 Mil PE Ratio: 0 PB Ratio: 6.54 GF Score: 47/100

Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call Transcript

Jul 01, 2021 / 12:30PM GMT
Release Date Price: $22.6 (-5.24%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised that this conference call is being recorded. I would now like to hand the conference over to your speaker for today, Dr. Carlo Tanzi of Investor Relations. Carlo, please go ahead.

Carlo Tanzi
Seres Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, and good morning. A press release announcing that Seres has entered into a license agreement with Nestlé Health Science, who we'll be referring to as Nestlé, to co-commercialize SER-109 became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website.

I'd like to remind you that we'll be making forward-looking statements relating to the timing, enrollment and results of our clinical studies, regulatory approval, the promise and potential impact of SER-109, including the potential market size, any potential benefits of collaborating with Nestlé, potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot